GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
N

Net Medical Xpress Solutions NMXS · USD

Health Care · US listing · 🇺🇸 United States

Compare

0.00

—

Close of 4 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in USD, from our data supplier.

FY2023

Revenue

$597,000

FY2014FY2023

Net income

−$1.9m

FY2014FY2023

Free cash flow

−$708,000

FY2014FY2023

Shareholders' equity

−$185,000

FY2014FY2023

Income statement

Fiscal years

FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016FY2015FY2014
Revenue$597,000$5.2m$1.8m$1.1m$1.6m$2.1m$2.8m$3.0m$4.2m$4.6m
Gross profit−$60,000$3.2m$679,000$204,000$344,000$560,000$939,000$771,000$1.2m$818,000
Research and development$18,000$17,000$18,000$19,000$15,000$9,000$66,000$87,000$100,000$121,000
Operating income−$1.8m$1.1m−$82,000−$603,000−$259,000−$2,000$105,000−$335,000$160,000−$466,000
Net income−$1.9m$885,000$10,000−$499,000−$265,000−$11,000$95,000−$344,000$151,000−$482,000
Diluted earnings per share-0.050.020.00-0.01-0.01-0.000.00-0.020.01-0.03

Balance sheet

At each fiscal year end

FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016FY2015FY2014
Total assets$893,000$3.0m$1.5m$671,000$835,000$792,000$820,000$820,000$1.2m$1.2m
Cash and short-term investments$288,000$1.1m$411,000$335,000$282,000$333,000$251,000$307,000$410,000$277,000
Total liabilities$1.1m$1.3m$938,000$383,000$461,000$333,000$350,000$467,000$610,000$927,000
Debt$949,000$1.0m$850,000$261,000$94,000$51,000$68,000$60,000$70,000$90,000
Shareholders' equity−$185,000$1.7m$516,000$288,000$403,000$459,000$470,000$353,000$591,000$312,000
Shares outstanding38m38m34m38m38m20m20m19m19m16m

Cash flow

Fiscal years

FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016FY2015FY2014
Cash from operations−$690,000$833,000−$316,000−$131,000−$179,000$81,000−$50,000−$80,000$131,000−$179,000
Capital spending−$18,000−$131,000−$103,000−$2,000−$1,000—−$13,000−$13,000−$13,000−$9,000
Free cash flow−$708,000$702,000−$419,000−$133,000−$180,000$81,000−$63,000−$93,000$118,000−$188,000

Latest quarters

By quarter end

Mar 2024Dec 2023Sept 2023Jun 2023Mar 2023Dec 2022Sept 2022Jun 2022
Revenue$3,000$64,000$147,000$160,000$226,000$733,000$1.0m$1.5m
Gross profit−$52,000−$33,000−$1,000−$18,000−$9,000$252,000$540,000$947,000
Operating income−$193,000−$245,000−$491,000−$766,000−$319,000−$212,000$94,000$342,000
Net income−$202,000−$254,000−$493,000−$776,000−$334,000−$472,000$211,000$403,000
Diluted earnings per share-0.01-0.01-0.01-0.02-0.01-0.010.010.01
Total assets$666,000$893,000$1.1m$1.7m$2.6m$3.0m$3.5m$3.2m
Cash and short-term investments$159,000$288,000$489,000$629,000$835,000$1.1m$1.3m$788,000
Debt$296,000$280,000$219,000$210,000$199,000$185,000$172,000$139,000
Shareholders' equity−$387,000−$185,000$69,000$562,000$1.3m$1.7m$2.1m$1.9m

Growth per year

Compound annual rate

3 years5 years10 years
Revenue-18.9%-22.2%-18.8%
Operating income44.5%290.7%—
Net income55.0%178.9%—

Average margins

Over each period

1 year3 years5 years10 years
Gross margin53.7%46.0%39.4%30.6%
Operating margin-12.7%-16.4%-13.5%-6.8%
Net margin-16.7%-16.8%-14.0%-7.2%

Valuation history

At each fiscal year end

FY2021
Price to earnings0.0

Share price return

Finished calendar years

2025202420232022202120202019201820172016
Return-95%5188%92%234%119%159%546%125%166%-49%

Dividends and splits

Per share, in the currency the company pays

Paid for 0 years.

  • 9-to-1 reverse split · 20 Jun 2016

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.